Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H-S Shiah

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer Letters|January 1, 1991
Modulatory effect of crocetin on aflatoxin B1 cytotoxicity and DNA adduct formation in C3H10T1/2 fibroblast cellC J Wang, H S Shiah, J K Lin
Biochemical Pharmacology|August 15, 1990
Effect of ethanol on hepatotoxicity and hepatic DNA-binding of aflatoxin B1 in ratsC J Wang, S W Wang, H S Shiah, et al.
The Journal of Biological Chemistry|November 25, 1992
Pseudomonas exotoxin A-epidermal growth factor (EGF) mutant chimeric protein as an indicator for identifying amino acid residues important in EGF-receptor interactionH S Shiah, T Y Chen, C M Chang, et al.
European Journal of Cancer Care|November 9, 2005
Pulmonary embolism after transcatheter arterial chemoembolizationH-S Shiah, T-W Liu, L-T Chen, et al.
Alimentary Pharmacology & Therapeutics|August 11, 2005
alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinomaL-T Chen, T-W Liu, Y Chao, et al.
Alimentary Pharmacology & Therapeutics|November 9, 2012
Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinomaH-S Shiah, C-Y Chen, C-Y Dai, et al.
Cancer Chemotherapy and Pharmacology|January 12, 2015
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patientsT C Chang, H S Shiah, C H Yang, et al.
Leukemia|February 13, 2002
Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23H-S Shiah, Y-Y Kuo, J-L Tang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerJ S Chen, C Hsu, N J Chiang, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer Letters|January 1, 1991
Modulatory effect of crocetin on aflatoxin B1 cytotoxicity and DNA adduct formation in C3H10T1/2 fibroblast cellC J Wang, H S Shiah, J K Lin
Biochemical Pharmacology|August 15, 1990
Effect of ethanol on hepatotoxicity and hepatic DNA-binding of aflatoxin B1 in ratsC J Wang, S W Wang, H S Shiah, et al.
The Journal of Biological Chemistry|November 25, 1992
Pseudomonas exotoxin A-epidermal growth factor (EGF) mutant chimeric protein as an indicator for identifying amino acid residues important in EGF-receptor interactionH S Shiah, T Y Chen, C M Chang, et al.
European Journal of Cancer Care|November 9, 2005
Pulmonary embolism after transcatheter arterial chemoembolizationH-S Shiah, T-W Liu, L-T Chen, et al.
Alimentary Pharmacology & Therapeutics|August 11, 2005
alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinomaL-T Chen, T-W Liu, Y Chao, et al.
Alimentary Pharmacology & Therapeutics|November 9, 2012
Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinomaH-S Shiah, C-Y Chen, C-Y Dai, et al.
Cancer Chemotherapy and Pharmacology|January 12, 2015
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patientsT C Chang, H S Shiah, C H Yang, et al.
Leukemia|February 13, 2002
Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23H-S Shiah, Y-Y Kuo, J-L Tang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerJ S Chen, C Hsu, N J Chiang, et al.
Pageof 1